Cargando…
Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation
Parkinson's disease (PD) is characterized by the selective loss of dopamine neurons in the substantia nigra; however, the mechanism of neurodegeneration in PD remains unclear. A subset of familial PD is linked to mutations in PARK2 and PINK1, which lead to dysfunctional mitochondria-related pro...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063469/ https://www.ncbi.nlm.nih.gov/pubmed/27641647 http://dx.doi.org/10.1016/j.stemcr.2016.08.012 |
_version_ | 1782459984516218880 |
---|---|
author | Chung, Sun Young Kishinevsky, Sarah Mazzulli, Joseph R. Graziotto, John Mrejeru, Ana Mosharov, Eugene V. Puspita, Lesly Valiulahi, Parvin Sulzer, David Milner, Teresa A. Taldone, Tony Krainc, Dimitri Studer, Lorenz Shim, Jae-won |
author_facet | Chung, Sun Young Kishinevsky, Sarah Mazzulli, Joseph R. Graziotto, John Mrejeru, Ana Mosharov, Eugene V. Puspita, Lesly Valiulahi, Parvin Sulzer, David Milner, Teresa A. Taldone, Tony Krainc, Dimitri Studer, Lorenz Shim, Jae-won |
author_sort | Chung, Sun Young |
collection | PubMed |
description | Parkinson's disease (PD) is characterized by the selective loss of dopamine neurons in the substantia nigra; however, the mechanism of neurodegeneration in PD remains unclear. A subset of familial PD is linked to mutations in PARK2 and PINK1, which lead to dysfunctional mitochondria-related proteins Parkin and PINK1, suggesting that pathways implicated in these monogenic forms could play a more general role in PD. We demonstrate that the identification of disease-related phenotypes in PD-patient-specific induced pluripotent stem cell (iPSC)-derived midbrain dopamine (mDA) neurons depends on the type of differentiation protocol utilized. In a floor-plate-based but not a neural-rosette-based directed differentiation strategy, iPSC-derived mDA neurons recapitulate PD phenotypes, including pathogenic protein accumulation, cell-type-specific vulnerability, mitochondrial dysfunction, and abnormal neurotransmitter homeostasis. We propose that these form a pathogenic loop that contributes to disease. Our study illustrates the promise of iPSC technology for examining PD pathogenesis and identifying therapeutic targets. |
format | Online Article Text |
id | pubmed-5063469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-50634692016-10-19 Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation Chung, Sun Young Kishinevsky, Sarah Mazzulli, Joseph R. Graziotto, John Mrejeru, Ana Mosharov, Eugene V. Puspita, Lesly Valiulahi, Parvin Sulzer, David Milner, Teresa A. Taldone, Tony Krainc, Dimitri Studer, Lorenz Shim, Jae-won Stem Cell Reports Article Parkinson's disease (PD) is characterized by the selective loss of dopamine neurons in the substantia nigra; however, the mechanism of neurodegeneration in PD remains unclear. A subset of familial PD is linked to mutations in PARK2 and PINK1, which lead to dysfunctional mitochondria-related proteins Parkin and PINK1, suggesting that pathways implicated in these monogenic forms could play a more general role in PD. We demonstrate that the identification of disease-related phenotypes in PD-patient-specific induced pluripotent stem cell (iPSC)-derived midbrain dopamine (mDA) neurons depends on the type of differentiation protocol utilized. In a floor-plate-based but not a neural-rosette-based directed differentiation strategy, iPSC-derived mDA neurons recapitulate PD phenotypes, including pathogenic protein accumulation, cell-type-specific vulnerability, mitochondrial dysfunction, and abnormal neurotransmitter homeostasis. We propose that these form a pathogenic loop that contributes to disease. Our study illustrates the promise of iPSC technology for examining PD pathogenesis and identifying therapeutic targets. Elsevier 2016-09-15 /pmc/articles/PMC5063469/ /pubmed/27641647 http://dx.doi.org/10.1016/j.stemcr.2016.08.012 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Chung, Sun Young Kishinevsky, Sarah Mazzulli, Joseph R. Graziotto, John Mrejeru, Ana Mosharov, Eugene V. Puspita, Lesly Valiulahi, Parvin Sulzer, David Milner, Teresa A. Taldone, Tony Krainc, Dimitri Studer, Lorenz Shim, Jae-won Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation |
title | Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation |
title_full | Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation |
title_fullStr | Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation |
title_full_unstemmed | Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation |
title_short | Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation |
title_sort | parkin and pink1 patient ipsc-derived midbrain dopamine neurons exhibit mitochondrial dysfunction and α-synuclein accumulation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063469/ https://www.ncbi.nlm.nih.gov/pubmed/27641647 http://dx.doi.org/10.1016/j.stemcr.2016.08.012 |
work_keys_str_mv | AT chungsunyoung parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT kishinevskysarah parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT mazzullijosephr parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT graziottojohn parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT mrejeruana parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT mosharoveugenev parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT puspitalesly parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT valiulahiparvin parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT sulzerdavid parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT milnerteresaa parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT taldonetony parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT kraincdimitri parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT studerlorenz parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation AT shimjaewon parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation |